Chinese-Made Unitree G1 Humanoid Robots Just Performed the World's First Live-Pig Gallbladder Surgery — What This Means for Surgical Robotics in China

Published: July 13, 2026 · Source: Nature (UC San Diego study), July 12, 2026; ibtimes.sg, July 12, 2026

Researchers at the University of California San Diego used two Chinese-made Unitree G1 humanoid robots — teleoperated by surgeons — to successfully remove gallbladders from live pigs. Published in Nature in July 2026 and reported by IBTimes Singapore on July 12, this is the first demonstration anywhere of general-purpose humanoid robots performing laparoscopic cholecystectomy on living tissue. The platform is not a purpose-built surgical machine. It is a $16,000 commercial humanoid retrofitted with surgical instruments, made by Hangzhou's Unitree Robotics.

What the UC San Diego team actually did

The UC San Diego Advanced Robotics and Controls Lab, working with the university's Center for the Future of Surgery, ran two sets of experiments. In one, a single G1 humanoid worked alongside a human surgeon. In the second, two G1 humanoids completed the procedure together — surgeon teleoperating both units in concert.

Both procedures were fully teleoperated. The surgeons sat at a control console and sent motion commands to the robots over a network. The robots, which stand about 1.3 meters tall and weigh 35 kilograms, retracted tissue, dissected and clipped structures, and removed the gallbladder from the liver bed. The animals survived the procedures.

"As a proof of concept, it absolutely worked," said Dr. Ryan Broderick, interim director of the Center for the Future of Surgery at UC San Diego, in comments to ABC News. The team's GitHub overview adds: "Humanoid form factors offer unique potential, particularly for assisting with surgical tasks. Traditionally, robotic systems for surgery are purpose-built platforms such as Intuitive Surgical's da Vinci Surgical System, and it remains unclear how close current humanoid systems are to meeting the precision, control, and safety requirements of minimally invasive surgery."

Colorectal surgeon Dr. Shanglei Liu, one of the procedure leads, told IBTimes the deployment scenario the team envisions: "You can imagine this device being deployed on a ship, in a village somewhere, in a smaller operating environment that's not in major cities." UC San Diego professor Michael Yip framed the broader claim: "I believe we've shown that it is possible to use humanoid robots in an operating room to do real procedures that can eventually save lives."

Why the robot being Chinese is the entire story

Unitree Robotics was founded in 2016 in Hangzhou, Zhejiang, by Wang Xingxing. By mid-2026 it had shipped more than 10,000 quadruped and humanoid robots globally — more than any competitor, including Boston Dynamics, Agility Robotics, and Figure AI. The G1, launched in 2024 at a starting price around $16,000, is the cheapest dexterous humanoid commercially available with a credible manipulation package.

This pricing matters more than the technology itself for the medical question. A da Vinci Xi system costs hospitals $1.5 million to $2.5 million before instruments and service contracts. A da Vinci SP (single-port) lists at $2.0 million to $3.5 million. Maintenance contracts run $100,000 to $300,000 per year. A G1 with surgical add-ons costs less than a single year of da Vinci service.

Three structural consequences follow for China:

1. Domestic supply chain dominance. Unitree's manufacturing is in Hangzhou with a parts ecosystem within a two-hour drive of Shanghai. No Chinese hospital using G1 platforms faces the kind of tariff, export-control, or service-disruption risk that hangs over Intuitive Surgical's US-made da Vinci line. US-China tensions in 2025–2026 have already produced concrete export-control friction on surgical robotics components.

2. Procurement cycle asymmetry. Chinese tertiary hospitals can add a humanoid platform to a surgical department in weeks. US hospital capital committees take 6–18 months to approve a $2 million line item. A $16,000 platform falls below many Chinese hospital departments' discretionary spending limit entirely.

3. State policy alignment. Surgical robotics has been a designated strategic priority under Made in China 2025 since 2015, and the 14th Five-Year Plan (2021–2025) extended that designation through 2030. The 15th Five-Year Plan, in draft as of mid-2026, is widely expected to add humanoid robotics explicitly. NMPA's Center for Medical Device Evaluation has a dedicated surgical robotics fast-track review pathway, modeled on the FDA's Breakthrough Device Program but with shorter review windows for domestically produced systems.

How this connects to what Chinese hospitals already do

Chinese tertiary hospitals are not waiting for humanoids to scale up robotic surgery. They already do.

Beijing United Family Hospital, Peking University Third Hospital, Huashan Hospital (affiliated with Fudan University), and Ruijin Hospital (Shanghai Jiao Tong University) all run high-volume da Vinci programs. The Microport Toumai single-port robot — the first domestically produced NMPA-approved surgical robot — has been in routine use at Shanghai Changhai Hospital, the First Affiliated Hospital of Sun Yat-sen University, and others since 2024. Edge Medical's portfolio of laparoscopic and orthopedic robots is in the same hospital cohort.

What the UC San Diego study changes is the type of robot that will eventually sit next to the da Vinci in those operating rooms. A humanoid is not a replacement for a purpose-built surgical system — the precision, control, and safety requirements are different. But it is a complement. Two surgical roles the UC San Diego work points toward:

Surgical training and proctoring. A teleoperated humanoid lets a senior surgeon at a major center guide a procedure at a remote or lower-resource hospital — exactly the deployment scenario Dr. Liu described. China's existing 5G remote-surgery infrastructure (Tongji Hospital's 2025 Wuhan-to-Hyderabad tele-proctoring demonstrations, the Ruijin-Shanghai Cancer Center robotic training network) gives the hardware a pre-built deployment corridor.

Instrument handling and bedside support. A humanoid stationed in the OR can pass instruments, hold retractors, manage the camera, and handle specimen bags — tasks that today occupy a circulating nurse or a surgical tech. That capability compounds: one humanoid doing instrument handling frees two humans for higher-skill work, which compresses case time and reduces staffing pressure on Chinese ORs already running at 90%+ utilization.

What this does not change (yet)

The Nature paper is explicit: there are "key technical challenges that must be addressed before clinical deployment." The G1's manipulation precision, force feedback, sterilization compatibility, and failure-mode handling are all preclinical. The team nicknamed the robots "Surgie" and framed them as an "impressive demonstration rather than a replacement for human surgeons."

Three things to keep in mind before a Chinese hospital patient sees a humanoid in the OR:

The pig-to-human gap is large. Pig anatomy is similar to human anatomy for many procedures, but not all. Pig gallbladders are easier to access than human gallbladders (smaller abdominal cavity, less visceral fat in young research pigs). Human laparoscopic cholecystectomy is harder. The first human cases, if any, are at minimum 3–5 years out and will require regulatory approvals NMPA has not yet defined.

Sterility is unsolved. General-purpose humanoids are not built for sterile fields. Sterilizable covers, instrument-pass-through ports, and intraoperative cleaning protocols do not exist in the G1 product line. Developing these is non-trivial — da Vinci's sterile draping and instrument-exchange system is itself decades of iteration.

Malpractice and consent frameworks are not built. When a surgeon teleoperates a humanoid across a network, the failure-mode analysis is novel. Network latency, command-loss, mechanical drift, and sterility breach all need new malpractice and informed-consent language. Chinese hospital ethics committees, NMPA, and the Chinese Medical Doctor Association have not yet published guidance on humanoid surgical teleoperation.

What international surgical patients should actually do today

The headlines are real, the platform is real, and the Chinese supply chain is real. None of that translates into a humanoid performing surgery on a patient this year or next. What translates into care available today, in mid-2026, at Chinese hospitals:

Da Vinci robotic prostatectomy, partial nephrectomy, hysterectomy, and colorectal resection. Routinely performed across the top 30 Chinese tertiary hospitals. Outcomes data from Chinese centers now published in journals indexed in PubMed and the Chinese Medical Journal show complication and recovery profiles equivalent to or better than US benchmarks, at roughly one-third to one-half the all-in cost.

Microport Toumai single-port robotic surgery. Available at Changhai Hospital (Shanghai), the First Affiliated Hospital of Sun Yat-sen University (Guangzhou), and several other leading centers. Toumai is positioned as a da Vinci alternative for high-volume urology and gynecology, and Chinese pricing for the system is reportedly 40–60% lower than da Vinci Xi.

5G remote proctoring and tele-mentoring. Tongji Hospital's Wuhan hub has run live tele-proctored procedures since 2024, and the network is expanding to Belt and Road partner hospitals in the UAE, Saudi Arabia, Indonesia, and Central Asia. For international patients in those regions, the option to have a Chinese surgeon's expertise applied to a procedure performed by a local team is now real.

Robotic microsurgery at HKUMed Queen Mary Hospital. Hong Kong's Queen Mary Hospital completed the world's first robotic living-donor liver transplant in mid-2026, using the CMR Versius platform. The Greater China microsurgery corridor — HKUMed QMH, Shanghai Changhai, Beijing 301 — is now the global reference center for robotic hepatobiliary and reconstructive work.

For the international patient, the humanoid story is a signal, not a service. The signal is that the Chinese robotics ecosystem — Unitree, Microport, Edge Medical, and a dozen smaller firms — has crossed a credibility threshold in surgical research. The service that translates to a hospital bill in 2026 is still purpose-built surgical robotics. Chinese hospitals do more of it, at lower cost, than most other systems in the world.

What to watch in the next 12–18 months

Four concrete data points worth tracking:

1. NMPA surgical robotics approvals in 2026–2027. Watch the NMPA Center for Medical Device Evaluation's quarterly approval lists. Any domestically produced humanoid surgical platform — or any surgical instrument system specifically designed for humanoid use — clearing an NMPA review is the first signal that clinical use is closer than 3–5 years out.

2. Unitree's medical-robotics partnerships. Unitree has not formally announced a medical vertical. If the company partners with a Chinese academic medical center (Peking University Third Hospital, Huashan, or Ruijin are the likely candidates) for a formal surgical robotics program, the timeline shortens. Watch for any university-industry collaboration announcement in the second half of 2026.

3. The 15th Five-Year Plan's humanoid-robotics language. The plan is in draft as of mid-2026. Surgical and medical use cases being named explicitly would unlock state funding, procurement fast-tracking, and regulatory pathway definition. Watch for the plan's publication, expected late 2026 or early 2027.

4. International clinical trials using humanoid platforms. The UC San Diego team has signaled interest in multi-center follow-up. If a Chinese site joins as a partner — and the Unitree supply advantage makes this likely — the first Chinese-institution clinical trial of a teleoperated humanoid surgical system could begin enrolling in late 2027 or 2028.

Bottom line for international patients

The world's first humanoid surgical procedure was done with a Chinese robot. That fact will not change a single patient's treatment plan in 2026. What it changes is the trajectory. Chinese hospital systems will be the first to integrate general-purpose humanoids into surgical workflows — for training, instrument handling, and tele-proctoring first, then for selected surgical steps under controlled conditions. The clinical access for international patients follows a year or two behind that integration.

If you are weighing robotic surgery today and cost, capacity, and outcome data are the deciding factors, Chinese tertiary hospitals are already the right call. If you are weighing whether to wait for the humanoid surgical era, the honest answer is: it is real, but it is not a clinical product yet. The first human cases are 3–5 years away, and the first patient with an international travel budget should plan around 2029–2030, not 2026.